Last updated: February 13, 2026
What is NDC 59651-0217?
NDC 59651-0217 corresponds to Aflibercept Injection, marketed under the brand name Eylea. It is an angiogenesis inhibitor used primarily to treat neovascular age-related macular degeneration, diabetic retinopathy, central retinal vein occlusion, and other eye conditions involving abnormal blood vessel growth.
Market Overview
Market Size and Segments
The global ophthalmic drug market, including intravitreal injections like Aflibercept, was valued at approximately $8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5% through 2027 [1].
Key competitors include:
- Ranibizumab (Lucentis): Market leader with an estimated 50% market share.
- Bevacizumab (Avastin): Off-label use, significant revenue due to lower price.
- Aflibercept (Eylea): Approximate 30–35% market share among anti-VEGF agents.
Pricing and Reimbursement Dynamics
Average wholesale prices (AWP) for Eylea vary by dosage but are generally around $1,900 to $2,200 per injection. Insurance coverage, PBMs, and pharmacy benefit managers influence outpatient retail prices.
In the U.S., the average list price for a standard dose (2 mg/0.05 mL) is approximately $2,000. Reimbursement under Medicare and private insurance typically covers most of this, with patient co-payments around $20–$50 for insured individuals.
Current Price Trends
- The price per injection has remained relatively stable over the past two years.
- Recent efforts to introduce biosimilars have not yet impacted pricing significantly due to the lack of approved biosimilar versions for Eylea.
- Medicaid and other public programs negotiate lower prices, approximately 20–30% discounts off list prices.
Market Drivers and Constraints
Drivers:
- Increasing prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.
- Growing awareness and improved diagnosis.
- Expanded insurance coverage.
Constraints:
- Off-label use of cheaper alternatives (Bevacizumab).
- Patent exclusivity until at least 2027 in the U.S.
- Potential biosimilar entry, which could pressure prices post-2027.
Price Projections (2023-2027)
| Year |
Projected Average Price per Injection |
Notes |
| 2023 |
$2,000 |
Stable due to current patent protections. |
| 2024 |
$1,950 |
Slight decline anticipated as market stabilizes. |
| 2025 |
$1,900 |
Introduction of biosimilar competitors expected. |
| 2026 |
$1,800 |
Biosimilar competition increases; pricing pressure intensifies. |
| 2027 |
$1,700 |
Patent expiration; biosimilars gain market share. |
Impact of Biosimilars
Biosimilars for Eylea are in development. FDA approval could occur by 2025–26, with entry into the market potentially reducing prices by 30–50% for branded Aflibercept.
Regulatory and Policy Factors
- Patent protections are critical; patent expirations in 2027 could dramatically reduce prices.
- CMS policies to favor biosimilars and reduce drug costs could accelerate price erosion.
- Medicare and Medicaid negotiations have historically negotiated discounts, influencing market dynamics.
Key Takeaways
- The current market for NDC 59651-0217 (Eylea) is stable with growth driven by rising ocular disease prevalence.
- Prices are trending downward slightly, with a significant drop expected after patent expiration.
- Biosimilar entry remains the primary risk factor that could reduce drug prices by up to 50% by 2027.
- Reimbursement and insurance policies will influence retail prices.
- Market segmentation favors branded Eylea in the short term, transitioning to biosimilars post-2027.
FAQs
1. When is patent expiration for Eylea, and how will it impact prices?
Patent protection is expected to expire in 2027 in the U.S. Post-expiration, biosimilar entrants could reduce prices by 30–50%.
2. What are the main competitors of NDC 59651-0217?
Ranibizumab (Lucentis) and off-label Bevacizumab (Avastin) are primary competitors. Biosimilars for these drugs are in development but not yet impacting Eylea’s market.
3. How does insurance coverage influence the price of Eylea?
Insurance, including Medicare and private plans, negotiates discounts, reducing patient co-pays from the list price.
4. Are biosimilars approved for Eylea?
No biosimilars for Eylea currently have FDA approval. Multiple candidates are in late-stage development.
5. What factors could change the current market outlook?
Regulatory changes, biosimilar approvals, patent litigation, or new therapies could alter pricing and market share dynamics.
References
[1] Research and Markets, 2022. Ophthalmic Drugs Market Report, 2022-2027.
